Yesterday, a Director at Invitae (NVTA), Eric Aguiar, sold shares of NVTA for $135K.
Following Eric Aguiar’s last NVTA Sell transaction on November 21, 2016, the stock climbed by 7.2%.
See today’s analyst top recommended stocks >>
Based on Invitae’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $37.37 million and GAAP net loss of $31.72 million. In comparison, last year the company earned revenue of $18.15 million and had a GAAP net loss of $27.4 million. Currently, Invitae has an average volume of 958.4K.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $18.19, reflecting a 29.9% upside.
The insider sentiment on Invitae has been negative according to 23 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headuartered in San Francisco, CA.
